Published May 11, 2020
After 10 months of investigation, the Federal Trade Commission cleared AbbVie Inc.‘s $63 billion deal to buy Allergan plc. Fractured opinions about the deal from the five commissioners highlight, however, a broader disagreement about the role of antitrust in regulating pharmaceutical markets.